Monoclonal immunoglobulins (mAbs) rank among biology and medicine’s most potent and extensively utilized tools, leveraging mammalian immunity’s intrinsic self / non-self discrimination. For mAb generation, immunized animals yield splenocytes (e.g., B lymphocytes) that undergo fusion with myeloma cells. Post-fusion, numerous subclones undergo antigen-specificity screening. Following hybridoma line identification, functional characterization precedes manufacturing-scale expansion. To date, thousands of clinically deployed mAbs have undergone multi-purpose characterization. Specifically, glycan-targeting monoclonal antibodies represent ideal cancer therapeutics due to saccharide antigens overexpressed across diverse malignancies.